Oligonucleotide News and Research

RSS

Picoquant invests in Fluobrick Solutions to simplify access to single molecule research

PicoQuant GmbH announces its investment in FluoBrick Solutions GmbH, a newly founded Berlin-based start-up focused on giving life science researchers in academia and pharma diagnostics access to the power of single molecule techniques.

25 Sep 2025

Scientists unveil new obesity drug that reprograms fat and energy use

Details of a new drug that aims to treat the underlying causes of obesity are being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September).

18 Sep 2025

Aptamer signs therapeutic development agreement with Invizius

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce that it has signed a new therapeutic development agreement with Invizius, a clinical-stage biotechnology company focused on second-generation complement system therapies for inflammatory, fibrotic, and autoimmune diseases.

From Aptamer Group 2 Sep 2025

First clinical trial in cats tests targeted therapy for deadly head and neck cancer

Researchers have reported results from the first-ever clinical trial of a new class of targeted therapy in pet cats with head and neck squamous cell carcinoma (HNSCC)-a cancer which is notoriously deadly and difficult to treat.

28 Aug 2025

Aptamer Group introduces novel biomarker discovery service

Aptamer Group plc, the leading developer of next-generation synthetic binders delivering innovation to the life science industry, today announced the launch of its biomarker discovery service, offering researchers in pharmaceutical, biotechnology, and diagnostic development an innovative approach to identify and validate new disease markers.

28 Aug 2025

Scientists discover molecular brake that halts brain cell repair in multiple sclerosis

A team of scientists led by the Institute for Glial Sciences (IGS) at Case Western Reserve University's School of Medicine has discovered a built-in "brake" that controls when key brain cells mature.

25 Aug 2025

Breakthroughs in diagnosis and therapy for transthyretin amyloidosis

Transthyretin amyloidosis (ATTR) is caused by the misfolding and aggregation of the transthyretin (TTR) protein, leading to multi-organ damage.

21 Aug 2025

Triglycerides identified as direct cause of abdominal aortic aneurysms

High levels of triglycerides, the most common type of fat in the body and the foods we eat, directly cause abdominal aortic aneurysms, according to a study in mouse models led by Michigan Medicine.

14 Aug 2025

Characterization of antibodies targeting ASO modifications for intracellular trafficking

A new article in the peer-reviewed journal Nucleic Acid Therapeutics describes the characterization of antibodies targeting antisense oligonucleotide (ASO) phosphorothioate and 2'-methoxyehtyl modifications for intracellular trafficking and biodistribution studies.

1 Aug 2025

Experimental ALS drug shows unprecedented recovery in some patients

When Columbia neurologist and scientist Neil Shneider speaks to his ALS patients who volunteer for experimental therapies, he's unwaveringly honest.

23 May 2025

Aptamer announces new data at ASGCT

Aptamer Group plc, the leading developer of next-generation synthetic binders delivering innovation to the life science industry, presented new data on its Optimer therapeutic delivery vehicle for liver fibrosis at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in New Orleans, LA (13-17 May 2025).

From Aptamer Group 16 May 2025

ELRIG announces Prof Rory Johnson and Dr Shalini Andersson as keynote speakers at Therapeutic Oligonucleotides 2025

ELRIG, a not-for-profit, volunteer-led organization for the drug discovery community, today announced the keynote speakers for Therapeutic Oligonucleotides 2025 taking place at the AstraZeneca R&D site in Gothenburg, Sweden from 14-15 May. Prof Rory Johnson, Associate Professor, University College Dublin, and Dr Shalini Andersson, Vice President Nucleic Acid Therapeutics, AstraZeneca will lead this year's event focused on 'drugging the undruggable'.

25 Mar 2025

New approach to combat cancer by reactivating natural RNA kill switch

Alternative RNA splicing is like a movie editor cutting and rearranging scenes from the same footage to create different versions of a film.

14 Mar 2025

First insights into familial ALS in Egypt reveal genetic variations and disease progression

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive degeneration of motor neurons, leading to muscle weakness and eventually death.

18 Feb 2025

Researchers develop new approach to effectively deliver therapeutics into the brain

Researchers at the Icahn School of Medicine at Mount Sinai have developed an innovative approach - demonstrated in mouse models and isolated human brain tissue - to safely and effectively deliver therapeutics into the brain, providing new possibilities for treating a wide range of neurological and psychiatric diseases.

25 Nov 2024

Parkinson's disease drug disrupts the gut microbiome by inducing iron deficiency

In a groundbreaking new study, conducted within the framework of the FWF-funded Cluster of Excellence "Microbiomes drive Planetary Health", scientists from the University of Vienna, in collaboration with the University of Southampton, Aalborg University and Boston University, have revealed that the widely prescribed Parkinson's disease drug entacapone significantly disrupts the human gut microbiome by inducing iron deficiency.

22 Nov 2024

Why predictive retina models could be the future of IND applications

Discover how retina models are revolutionizing rare disease treatment and accelerating drug development.

From Newcells Biotech 22 Nov 2024

CHiTA assay identifies functional twister ribozymes

The "RNA world" hypothesis proposes that the earliest life on Earth may have been based on RNA - a single-stranded molecule similar in many ways to DNA - like some modern viruses. This is because, like DNA, RNA can carry genetic information, but, like a protein, it can also act as an enzyme, initiating or accelerating reactions.

5 Nov 2024

Novel gene therapy holds potential in treating patients with epilepsy

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.

9 Oct 2024

New triple-targeting pharmacological tool developed for cancer treatment

A study led by researchers of the Institute of Biomedicine of the University of Barcelona (IBUB) has developed a new pharmacological tool capable of simultaneously administering three oligonucleotide-based drugs, each acting against a different therapeutic target within the cell.

8 Oct 2024